Aptus Pharma H1 Results: Net Profit Surges 200% to ₹5.1 Crore as Revenue Hits ₹48.9 Crore

Key numbers

1-Year Return	830.69%Price Performance
Market Cap	₹826.8 CrPharmaceuticals
P/E Ratio	178.97Sector: 44.82
RSI	84.85Overbought Zone

Key highlights

• Net profit climbed 200% YoY to ₹5.1 crore for H1-27 compared to ₹1.7 crore in the same period last year
• Revenue from operations increased to ₹48.9 crore, exceeding the total audited revenue of FY26
• Operating margins moderated to 13.9% in H1-27 from 16.7% in the previous year's first half
• Shareholders approved a preferential issue of 16.02 lakh equity shares at ₹280 per share to raise ₹44.88 crore
• The company successfully completed a 3:2 bonus equity share issue in May 2026
• Promoter holding remains stable at 72.89% as of the end of the September 2026 half-year

Revenue Scales on National Expansion Strategy

Aptus Pharma Limited reported a significant scaling in its top-line performance for the half-year ended September 30, 2026, with revenue from operations reaching ₹48.9 crore. This figure represents a substantial increase compared to the ₹14.4 crore recorded in the corresponding period of the previous year and exceeds the total audited revenue of ₹46.57 crore reported for the entire 2025-26 fiscal year. The company is actively transitioning from a regional pharmaceutical distributor to a national enterprise, targeting a geographic coverage of 46% across India by March 2027.

This expansion is supported by a distribution-heavy model focused on marketing finished pharmaceutical formulations.

Strategic Fundraising and Capital Structure Updates

• The company issued 102.90 lakh bonus equity shares in May 2026 in a 3:2 ratio, increasing total outstanding shares to 171.50 lakh.
• Shareholders approved a preferential issue of 16.02 lakh equity shares at ₹280 per share on September 14, 2026, to raise ₹44.88 crore.
• Aptus Pharma is targeting 20% in-house manufacturing by March 2028 to shift from an asset-light contract manufacturing model.
• The firm aims to expand its product portfolio to over 500 formulations within the next three years to deepen its market presence.
• Management has set a long-term goal to achieve pan-India distribution and presence by March 2029.
• Application for in-principle approval for the preferential issue has been submitted to the BSE and is currently under process.

Executive Commentary on Operational Momentum

We are pleased to report a strong H1 performance, with revenue of ₹48.92 crore, EBITDA of ₹7.68 crore, PAT of over ₹5.07 crore, reflecting nearly twofold year-on-year revenue growth.

Market Performance and Valuation Metrics

The market performance of Aptus Pharma has reflected its operational scaling, with the stock price recording an 830.69% increase over the past year. As of October 20, 2026, the company holds a market capitalization of ₹826.8 crore. The stock is currently trading at a P/E ratio of 178.97, which sits significantly higher than the industry average P/E of 44.83.

Technical indicators show a Day RSI of 84.85, placing the stock in the overbought zone. Despite the high valuation multiples, the company maintained a net profit of ₹5.1 crore for the half-year, supported by a promoter holding that remains stable at 72.89%.

What to watch next

• Target of 46% geographic coverage across India by March 2027
• Achievement of 20% in-house manufacturing by March 2028
• Pan-India expansion and distribution network target by March 2029
• In-principle approval from BSE for the proposed preferential issue of 16.02 lakh shares

“Aptus Pharma continues its transition from a regional pharmaceutical company towards a broader national presence. As part of our planned expansion, we are targeting 46% geographic coverage across India by March 2027.”

Aptus Pharma · financial snapshot

Share price	₹482.1
Market capitalisation	₹826.80 Cr
Revenue (annual)	₹46.57 Cr
Net profit (annual)	₹4.62 Cr
P/E (TTM)	178.97×Sector 44.82×
Promoter holding	72.89%0.00% QoQ
FII holding	0%Current quarter

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.